Literature DB >> 30772380

A SUV39H1-low chromatin state characterises and promotes migratory properties of cervical cancer cells.

Calvin Rodrigues1, Chitra Pattabiraman1, Anjali Vijaykumar1, Reety Arora1, Suma Mysore Narayana2, Rekha V Kumar2, Dimple Notani1, Patrick Varga-Weisz3, Sudhir Krishna4.   

Abstract

Metastatic progression is a major cause of mortality in cervical cancers, but factors regulating migratory and pre-metastatic cell populations remain poorly understood. Here, we sought to assess whether a SUV39H1-low chromatin state promotes migratory cell populations in cervical cancers, using meta-analysis of data from The Cancer Genome Atlas (TCGA), immunohistochemistry, genomics and functional assays. Cervical cancer cells sorted based on migratory ability in vitro have low levels of SUV39H1 protein, and SUV39H1 knockdown in vitro enhanced cervical cancer cell migration. Further, TCGA SUV39H1-low tumours correlated with poor clinical outcomes and showed gene expression signatures of cell migration. SUV39H1 expression was examined within biopsies, and SUV39H1low cells within tumours also demonstrated migratory features. Next, to understand genome scale transcriptional and chromatin changes in migratory populations, cell populations sorted based on migration in vitro were examined using RNA-Seq, along with ChIP-Seq for H3K9me3, the histone mark associated with SUV39H1. Migrated populations showed SUV39H1-linked migratory gene expression signatures, along with broad depletion of H3K9me3 across gene promoters. We show for the first time that a SUV39H1-low chromatin state associates with, and promotes, migratory populations in cervical cancers. Our results posit SUV39H1-low cells as key populations for prognosis estimation and as targets for novel therapies.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell migration; Cervical cancer; Chromatin; Genomics; Intratumoural heterogeneity; SUV39H1

Mesh:

Substances:

Year:  2019        PMID: 30772380     DOI: 10.1016/j.yexcr.2019.02.010

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 3.  Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression.

Authors:  Nirmalya Saha; Andrew G Muntean
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-26       Impact factor: 10.680

4.  H3K9me3 maintenance on a human artificial chromosome is required for segregation but not centromere epigenetic memory.

Authors:  Nuno M C Martins; Fernanda Cisneros-Soberanis; Elisa Pesenti; Natalia Y Kochanova; Wei-Hao Shang; Tetsuya Hori; Takahiro Nagase; Hiroshi Kimura; Vladimir Larionov; Hiroshi Masumoto; Tatsuo Fukagawa; William C Earnshaw
Journal:  J Cell Sci       Date:  2020-07-24       Impact factor: 5.285

5.  Reduction of miR-744 delivered by NSCLC cell-derived extracellular vesicles upregulates SUV39H1 to promote NSCLC progression via activation of the Smad9/BMP9 axis.

Authors:  Liming Gao; Qi Tian; Tong Wu; Shanshan Shi; Xiaobo Yin; Lijie Liu; Lei Zheng; Ping Wang; Yaling Tian; Shufeng Xu
Journal:  J Transl Med       Date:  2021-01-20       Impact factor: 5.531

6.  Clustering of Chromatin Remodeling Enzymes Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Pancreatic Cancer.

Authors:  Hui-Ching Wang; Hsiang-Yao Shih; Chun-Chieh Wu; Li-Tzong Chen; Chi-Wen Luo; Yi-Chang Liu; Jeng-Shiun Du; Min-Chin Huang; Yung-Yeh Su; Huan-Da Chen; Hui-Hua Hsiao; Sin-Hua Moi; Mei-Ren Pan
Journal:  Int J Med Sci       Date:  2022-09-21       Impact factor: 3.642

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.